selegiline / Generic mfg. - LARVOL DELTA

MAO-B inhibition by selegiline blunts cardiac functions improved by high-fat diet: Role of inflammation, apoptosis, and calcium-handling. (PubMed, Curr Res Pharmacol Drug Discov) - "HFD induced proapoptotic processes, which were restored by selegiline. In conclusion, moderate obesity improves cardiac function through Ca2+ homeostasis and inflammatory processes and MAO-B inhibition reverses these effects."

Journal • Cardiovascular • Genetic Disorders • Inflammation • Obesity • Oncology • TNFA

Bromocriptine, Selegiline and Amantadine in the Treatment of Depression-A Systematic Review. (PubMed, Pharmaceuticals (Basel)) - " Findings suggest that bromocriptine, amantadine, and selegiline may represent effective dopaminergic antidepressants, particularly for treatment-resistant or atypical depression. Further large-scale, methodologically rigorous studies are needed to confirm their clinical utility."

Journal • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

L-dopa induced iron accumulation in the ventral midbrain: the roles of sex and iron repletion (Neuroscience 2025) - "Vehicle (0.1% ascorbic acid), carbidopa+L-DOPA (5/20 mg/kg), or selegiline (0.3mg/kg) was administered via subcutaneous injection in all groups. These findings suggest that L-DOPA administration under iron-depleted-repleted conditions disrupts iron homeostasis by promoting iron uptake and reducing iron storage capacity, particularly in males. This sex-specific vulnerability to iron accumulation highlights the need for personalized PD therapies that consider both iron status and biological sex."

CNS Disorders • Movement Disorders • Parkinson's Disease • GFAP • TFRC

Current practices for diagnosis and management of Canine Cognitive Dysfunction Syndrome in the United States. (PubMed, Front Vet Sci) - "When managing their CCDS patients, pharmaceuticals are most often recommended, specifically selegiline...Results from this survey underscore there are still significant gaps in knowledge as to best practices for the diagnosis and management of CCDS. Clear CCDS diagnostic and management guidelines are needed to support veterinarians and address the therapeutic needs of patients."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Phenolic Derivatives of Astragalus aitosensis with Selective MAO-B Inhibition and Mitochondrial Protection. (PubMed, Molecules) - "Five of the phytochemicals-maackiain, cajanin, onogenin, afrormosin, and sayanedine-exhibited selective inhibition of human monoamine oxidase-B (MAO-B), with maackiain reducing activity by 45%, nearing the effect of selegiline...Structure-activity relationship (SAR) analysis highlighted the role of specific substituents and fused-ring systems in MAO-B inhibition. This study expands our knowledge of the phytochemical diversity of A. aitosensis and supports the therapeutic relevance of its phenolic compounds in neurodegenerative disorders such as Parkinson's disease."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Effectiveness of Medical Treatment on Survivability in Canine Cushing's Syndrome: A Systematic Review and Meta-Analysis. (PubMed, Animals (Basel)) - "Several pharmacological agents are available: trilostane, mitotane, ketoconazole, cabergoline, selegiline, and aminoglutethimide, but their comparative effects on survival remain unclear. In contrast, pooled survival rates at fixed intervals favored trilostane, with an 11% higher survival at 36 months (p = 0.005) and no heterogeneity observed (I2 = 0%). These findings suggest trilostane may offer long-term survival benefits over mitotane."

Journal • Retrospective data • Cushing’s Disease • Endocrine Disorders

Role of 5-Hydroxydecanoate in the Neuroprotective Activity of Diosmetin Against Rotenone-Induced Dopaminergic Toxicity in Rats. (PubMed, Protein Pept Lett) - "Diosmetin exhibits potent antioxidant and neuroprotective properties against rotenone-induced PD-like pathology. The combination of diosmetin and 5-HD offers a synergistic therapeutic potential, suggesting a promising approach for managing oxidative stress and mitochondrial dysfunction in PD."

Journal • Preclinical • CNS Disorders • Metabolic Disorders • Movement Disorders • Parkinson's Disease

Selective detection of Selegiline in Parkinson's patient urine via CuAAC-mediated fluorescence quenching of Azide-modified carbon dots. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "The method shows high selectivity against interferents and achieves excellent percentage recovery values reaching (96.0-97.0 %) when applied to urine samples. Most importantly, the method was successfully applied to urine samples from Parkinsonism patients, providing a non-invasive route for selegiline determination that offers significant advantages over traditional invasive sampling methods."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Treatment Stability Across Different ADD-ON Therapies in Fluctuating Parkinson's Disease (MDS Congress 2025) - "Objective: This study investigates the efficacy and tolerability of selegiline (SL), rasagiline (RS), safinamide (SF), and opicapone (OP) in fluctuating PD patients, focusing on treatment stability and demographic influences. No single add-on therapy demonstrated superior stability, highlighting comparable efficacy across options. Sex significantly influenced therapy adjustments, with females requiring more frequent modifications. These findings underscore the importance of personalized treatment strategies in fluctuating PD management."

CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Investigation of Baseline Factors Associated with a Favorable Response to Initial MAO-B Inhibitor Treatment in Parkinson's Disease (MDS Congress 2025) - " Among 44 sporadic PD cases, 21 received MAOBIs (selegiline: 13, rasagiline: 8), 18 received levodopa, and 5 received dopamine agonists. Patients with less orthostatic hypotension and preserved postganglionic cardiac sympathetic function were more likely to benefit from MAOBIs. Their MAO-A inhibitory effect may suppress norepinephrine metabolism, enhancing motor function via dopamine activation. Therefore, PD patients with mild orthostatic hypotension and mild MIBG myocardial scintigraphy abnormalities, where endogenous norepinephrine is retained, may experience greater motor symptom improvement with MAOBIs."

CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

L-DOPA Induced Iron Accumulation in the Ventral Midbrain: The Roles of Sex and Iron Repletion (MDS Congress 2025) - "Antiparkinsonian medications, L-DOPA, and a monoamine oxidase-B (MAO-B) inhibitor, selegiline are commonly used to treat PD... These findings suggest that L-DOPA administration under ID-IR conditions disrupts iron homeostasis by promoting iron uptake and reducing iron storage capacity, particularly in males. This sex-specific vulnerability to iron accumulation highlights the need for personalized PD therapies that consider both iron status and biological sex."

CNS Disorders • Movement Disorders • Parkinson's Disease • GFAP • TFRC

A multi-center, randomized, controlled study of the add-on effect of selegiline or zonisamide to L-dopa/DCI therapy in Parkinson's disease (DATSZ-PD study) (MDS Congress 2025) - "Selegiline or zonisamide have been suggested to have neuroprotective effects on dopamine neurons in patients with early PD. Motor function also tended to be preserved in both +SL and +ZN groups compared to LD alone group. Regarding QOL, mobility tended to be maintained in +SL group, and communication tended to be maintained in +SL and +ZN groups."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Monoamine oxidases are mediators of oxidative stress in human varicose Veins: interactions with obesity, inflammation, and angiotensin II. (PubMed, Mol Cell Biochem) - "Furthermore, the effect of selective MAO inhibition (clorgyline 10 μM for MAO-A, selegiline 10 μM for MAO-B) was tested ex vivo both at baseline and following acute stimulation with Ang II (100 nM)...In conclusion, MAO isoforms, in particular MAO-A, are upregulated in the human varicose veins and can be further induced by Ang II, especially in the setting of obesity associated with low-grade inflammation. MAO contributed to the local oxidative stress, which was significantly reduced by its pharmacological inhibition with MAO-A and B inhibitors, thus pointing to MAO as a potential therapeutic target in patients with CVD."

Journal • Genetic Disorders • Inflammation • Obesity • Varicose Veins • CRP

Utilizing Multiple Behavioral Endpoints to Identify Negative Control Chemicals in a Larval Zebrafish Behavior Assay. (PubMed, Toxics) - "This study evaluated nine chemicals with no reported evidence of mammalian developmental neurotoxicity, and a positive control (fluoxetine) for developmental and neurodevelopmental (i.e., behavioral) toxicity in zebrafish...Behavioral effects of developmental exposure to selegiline hydrochloride depended on the analysis method. Exposure to the other six chemicals (D-mannitol, glycerol, L-ascorbic acid, metformin hydrochloride, saccharin, and sodium benzoate), as well as ibuprofen or omeprazole, did not produce behavioral effects using either analysis method. Identifying negative control chemicals is essential for evaluating behavioral alterations precipitated by unknown substances and will assist with screening new chemicals for neurodevelopmental toxicity."

Journal

A Review of the Mechanisms and Risks of Panax ginseng in the Treatment of Alcohol Use Disorder. (PubMed, Diseases) - "Furthermore, KRG's neuromodulating role and influence on cytochrome P450 enzymes make it liable to interact with several medications, including warfarin, midazolam, selegiline, and serotonergic agents. Overall, KRG shows promise as a complementary supplement in managing aspects of AUD, though current evidence is limited by low sample sizes, inconsistent reports regarding nuances of ginsenosides' mechanisms, and a low number of human trials. Further human-focused research is needed to elucidate its safety, efficacy, and mechanism."

Journal • Review • Addiction (Opioid and Alcohol) • Cardiovascular • CNS Disorders • Hepatology • Liver Failure • Psychiatry

Modulating neuroinflammation through electroacupuncture: Mechanistic insights and pharmacological synergies. (PubMed, Curr Opin Pharmacol) - "Notably, EA has demonstrated synergistic potential when combined with pharmacologic agents such as l-DOPA, selegiline, donepezil, and minocycline, enhancing neuroprotective efficacy and reducing inflammatory and oxidative burdens. This highlights EA's potential integration into clinical strategies for treating neurodegenerative disorders. Understanding the neural circuits and immunological cascades engaged by EA may inform its future integration with pharmacotherapy in personalized neuroimmune interventions."

Journal • Review • CNS Disorders • Inflammation • NLRP3 • TLR4

The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents. (PubMed, Pharmacol Res Perspect) - "Therefore, this study evaluates the effects of the irreversible MAO-B inhibitor selegiline and rasagiline and their combinations with conventional therapies on androgen-insensitive (PC-3, DU145) and androgen-sensitive (22Rv1, LNCaP, VCaP) PAC cell lines...Combination with enzalutamide in 22Rv1, and with docetaxel in PC-3 demonstrated potentiating and additive effects, respectively. Selegiline reduced FOXA1 and GLUT1 mRNA expressions related to cancer progression and metabolism in both cell lines, increased the apoptosis-related BAX in PC-3, and decreased AR, EGFR, and SNAI2 in 22Rv1 linked to proliferation and metastasis. These findings suggest potential for selegiline repurposing in both androgen-sensitive and -insensitive PAC therapy by promoting apoptosis and inhibiting cancer growth and survival signals, respectively."

Journal • Preclinical • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • EGFR • FOXA1 • SLC2A1 • SNAI2

Add-on therapies to levodopa improve pain modulation in Parkinson's disease with motor fluctuations: A prospective cohort study. (PubMed, Parkinsonism Relat Disord) - "Pain processing is altered in pwPD, independently of subjective pain complaints. MAO-B inhibitors, particularly safinamide and rasagiline, appear to restore pain thresholds and improve QOL, supporting their role in managing pain in PD."

Journal • CNS Disorders • Fatigue • Mood Disorders • Movement Disorders • Pain • Parkinson's Disease • Psychiatry • COMT

Selegiline protects against isoproterenol-induced myocardial ischemia injury: a potential mechanistic role of the PI3K/AKT/mTOR signaling pathway. (PubMed, Res Pharm Sci) - "Selegiline administration could protect against myocardial ischemia, induced following isoproterenol injection, which is mediated through PI3K/AKT/mTOR signaling pathways. However, future study needs to focus more on the exact protective route of selegiline action."

Journal • Cardiovascular • Fibrosis • Immunology • Inflammation • Myocardial Ischemia • MB

Selegiline as an innovative drug for the treatment of inferior alveolar nerve injury: a randomized clinical trial. (PubMed, J Craniomaxillofac Surg) - "Selegiline hydrochloride may contribute to early neurosensory recovery after IAN injury, particularly in the lower lip. However, these benefits were limited to specific parameters and time points. Further studies are needed to validate its therapeutic potential."

Clinical • Journal • Orthopedics • Pain

Classical Paal-Knorr Cyclization for Synthesis of Pyrrole-Based Aryl Hydrazones and In Vitro/In Vivo Evaluation on Pharmacological Models of Parkinson's Disease. (PubMed, Molecules) - "The most prominent statistically significant hMAOB inhibitory effect was determined for 15a, 15d, and 15f, comparable to that of selegiline...The most active and least toxic representative (15d) was evaluated in vivo on Rotenone based model of Parkinson's disease. The results revealed no microscopically visible alterations in the ganglion and glial cells in the animals treated with rotenone in combination with 15d."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Cocaine craving and use during pharmacotherapy trials for cocaine use disorder: A multi-trajectory analysis. (PubMed, Drug Alcohol Depend) - "Trajectories of craving/drug use in clinical trials for cocaine use disorder are heterogeneous. Participants experiencing the greatest reduction in cocaine craving/use experienced the greatest improvement in other measures of drug use and psychosocial functioning, supporting the utility of reduced craving/use as a clinically relevant outcome in pharmacotherapy trials of people with cocaine use disorder."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry

Machine learning combining external validation to explore the immunopathogenesis of diabetic foot ulcer and predict therapeutic drugs. (PubMed, PLoS One) - "Potential therapeutic compounds were identified using the Connectivity Map database and tested through molecular docking and dynamics simulations. The study pinpointed selegiline, L-BSO, flunisolide, PP-30, and fluocinolone as promising therapeutic agents, offering new insights into the pathogenesis of diabetic foot ulcers (DFU) and potential therapeutic strategies."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • CCL20 • CXCL13 • FGFR2 • FGFR3 • IL17A • PLA2G2A • S100A8

Adolescent nicotine abstinence increases anxiety and depressive-like behaviors, alcohol consumption, oxidative stress and inflammatory response accompanied by attenuated serotonergic/dopaminergic and cholinergic function in rats. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry) - "Another interesting finding was enhancement of ethanol drinking in nicotine-abstained group, compared to saline-treated rats. Treatment by higher doses of selegiline/sertraline could markedly prevent the mentioned behavioral and biochemical consequences induced by nicotine abstinence."

Journal • Preclinical • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry

Neuroprotective and neurorestorative properties of Mesembryanthemum tortuosum in a Parkinson's disease zebrafish larvae model. (PubMed, J Ethnopharmacol) - "The M. tortuosum extracts and Zembrin® containing various levels of mesembrine alkaloids improved both locomotion and oxidative stress associated with PD in a zebrafish larvae model. Furthermore, the effects of L-dopa and selegiline as core treatments in the management of PD were further confirmed in this PD zebrafish larvae model."

Journal • CNS Disorders • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease